HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study
HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study is a paper indexed in PICO Portal from OpenAlex.
How many citations does HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study have?
HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study has 23 citations in the OpenAlex counts PICO Portal stores.
When was HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study published?
HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study has 2024 year in the PICO Portal index.
What is the open-access status of HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study?
HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study has hybrid oa status in the PICO Portal index.
What is the DOI of HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study?
The DOI for HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study is on the source record.
What is the PMID of HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study?
The PMID for HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study is on the source record.
What is the OpenAlex record for HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study?
The OpenAlex for HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study is on the source record.